The price of multiple sclerosis drugs is astronomical and rapidly rising. But some drugs are now off-patent, and generic or biosimilar formulations offer new, cheaper alternatives. But are they just as good? This video takes a look at drugs such as glatiramer acetate (copaxone/glatopa), tecfidera, gilenya, aubagio, and tysabri and their alternative formulations.
Is it better to take a “stronger” disease modifying therapy such as Tysabri or a “weaker” and more conservative disease modifying therapy? Many people who have low baseline disability prefer a cautious approach, but this study shows that the “stronger” drugs are actually better if taken by less disabled people early on
The article I am discussing: https://www.mdpi.com/1424-8247/14/2/8…
2:11 Rebif vs. Avonex
3:17 Betaseron vs. Avonex
3:54 Rebif 44mcg vs. Rebif 22cmg
4:30 Copaxone vs. Avonex
6:05 Copaxone vs Betaseron & Copaxone vs. Rebif
6:41 Gilenya vs. Avonex
8:23 Zeposia (ozanimod) vs. Avonex
9:00 Tecfidera Vs. Copaxone
10:22 Aubagio vs. Rebif
11:18 Imuran Vs. Avonex
12:16 Imuran vs. IFN
12:55 Tysabri vs. Avonex
14:53 Rebif + steroids
16:04 Laquinimod vs. Avonex
16:53 HSCT vs. Novantrone
19:01 HSCT vs. other DMTs
21:06 Lemtrada vs. Rebif
22:24 methotrexate vs. Avonex
23:16 Ocrevus vs. Rebif
24:28 Mavenclad (cladribine) vs. IFN